China SFDA Generics Report Acknowledges Industry And Regulator Have A Long Road Ahead
This article was originally published in PharmAsia News
A rare government report criticizes practices of China’s generics industry and SFDA, officially highlighting well-recognized problems – from a lengthy registration process to a lack of pricing and bidding incentives – which need urgent attention.
You may also be interested in...
To aid in ANDA assignments, OGD is developing a program to prioritize submissions as the agency addresses a 3,000-application backlog, OGD Deputy Director Robert West says during regulatory affairs specialists’ gathering in Seattle.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.